Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q1 2016 (← Previous) (Next →)

Filing Date: May 2, 2016

Total Value ($000): $144,173 (100.0% shares, 0.0% debt)

Holdings (11)

— Juno Therapeutics 32.5%

Value ($000) $46,832 Shares 1,229,512 Est. Cost $52.22 Unrealized —

— Paratek Pharmaceuticals 22.5%

Value ($000) $32,447 Shares 2,138,872 Est. Cost $38.55 Unrealized —

— Egalet 13.4%

Value ($000) $19,310 Shares 2,814,928 Est. Cost $6.01 Unrealized —

— FibroGen 12.1%

Value ($000) $17,504 Shares 822,175 Est. Cost $27.34 Unrealized —

— Nabriva Therapeutics 7.1%

Value ($000) $10,267 Shares 1,145,890 Est. Cost $9.50 Unrealized —

— ESSA Pharma 3.8%

Value ($000) $5,515 Shares 1,696,969 Est. Cost $5.22 Unrealized —

— Pieris Pharmaceuticals 3.3%

Value ($000) $4,720 Shares 2,483,949 Est. Cost $1.83 Unrealized —

EDIT Editas Medicine 2.5%

Value ($000) $3,627 Shares 105,007 Est. Cost $26.29 Unrealized 0.0%

— Proteon Therapeutics 1.3%

Value ($000) $1,935 Shares 250,000 Est. Cost $10.40 Unrealized —

— Dicerna Pharmaceuticals 0.8%

Value ($000) $1,198 Shares 223,457 Est. Cost $16.47 Unrealized —

— CymaBay Therapeutics 0.6%

Value ($000) $818 Shares 606,100 Est. Cost $1.94 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Juno Therapeutics	1,229,512	$46,832	32.5%	$52.22	—	Common Stock	48205A109
—	Paratek Pharmaceuticals	2,138,872	$32,447	22.5%	$38.55	—	Common Stock	699374302
—	Egalet	2,814,928	$19,310	13.4%	$6.01	—	Common Stock	28226B104
—	FibroGen	822,175	$17,504	12.1%	$27.34	—	Common Stock	31572Q808
—	Nabriva Therapeutics	1,145,890	$10,267	7.1%	$9.50	—	Sponsored ADR	62957M104
—	ESSA Pharma	1,696,969	$5,515	3.8%	$5.22	—	Common Stock	29668H104
—	Pieris Pharmaceuticals	2,483,949	$4,720	3.3%	$1.83	—	Common Stock	720795103
EDIT	Editas Medicine	105,007	$3,627	2.5%	$26.29	0.0%	Common Stock	28106W103
—	Proteon Therapeutics	250,000	$1,935	1.3%	$10.40	—	Common Stock	74371L109
—	Dicerna Pharmaceuticals	223,457	$1,198	0.8%	$16.47	—	Common Stock	253031108
—	CymaBay Therapeutics	606,100	$818	0.6%	$1.94	—	Common Stock	23257D103